What is Predicta Biosciences?
Predicta Biosciences is at the forefront of diagnostic innovation, developing advanced platforms that integrate single-cell genomics and liquid biopsy. This technology enables comprehensive whole-genome insights from blood or bone marrow samples. Their flagship GenoPredicta suite is designed for the non-invasive detection, characterization, and monitoring of hematologic malignancies, aiming to revolutionize how clinicians track disease progression and assess therapeutic response. This strategic financing positions the company for accelerated growth and market penetration in the precision oncology and diagnostics sector.
How much funding has Predicta Biosciences raised?
Predicta Biosciences has raised a total of $28.6M across 2 funding rounds:
Angel/Seed
$5.2M
Series A
$23.4M
Angel/Seed (2024): $5.2M with participation from Illumina Ventures
Series A (2025): $23.4M led by Engine Ventures, Mass General Brigham, Illumina Ventures, and Lightchain Capital
Key Investors in Predicta Biosciences
Illumina Ventures
Illumina Ventures is a leader in genomics and precision health investing, focused on building an ecosystem that translates investment into innovation to enhance human health. The company supports various portfolio companies that are advancing life science research, biopharmaceutical drug development, and gene editing technologies.
Engine Ventures
Engine Ventures is a venture firm that invests in Tough Tech founders who are addressing the world's most challenging problems through breakthrough technologies. The firm provides capital, operational expertise, and access to a robust network to help scale companies in foundational industries.
Mass General Brigham
Mass General Brigham operates as a leading integrated healthcare system dedicated to advancing patient care, medical research, and professional education within a unified organizational framework. The institution functions as a not-for-profit entity, with its mission centered on improving health outcomes.
What's next for Predicta Biosciences?
The recent major strategic investment signals a critical growth phase for Predicta Biosciences, likely enabling the company to scale its operations, expand its research and development capabilities, and further commercialize its GenoPredicta suite. This capital infusion is expected to bolster its position in the competitive landscape of diagnostic platforms, particularly in the hematologic malignancy market. Future developments may include broader clinical validation, strategic partnerships with healthcare providers, and expansion into new diagnostic applications.
See full Predicta Biosciences company page
